FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098334967> ?p ?o ?g. }

• W2098334967 endingPage "378" @default.
• W2098334967 startingPage "370" @default.
• W2098334967 abstract "We have designed and synthesized mixed backbone oligonucleotides (MBOs) containing 2′–5′-ribo- and 3′–5′-deoxyribonucleotide segments. Thermal melting studies of the phosphodiester MBOs (three 2′–5′ linkages at each end) with the complementary 3′–5′-DNA and -RNA target strands suggest that 2′–5′-ribonucleoside incorporation into 3′–5′-oligodeoxyribonucleotides reduces binding to the target strands compared with an all 3′–5′-oligodeoxyribonucleotide of the same sequence and length. Increasing the number of 2′–5′ linkages (from six to nine) further reduces binding to the DNA target strand more than the RNA target strand [Kandimalla,E.R. and Agrawal,S. (1996) Nucleic Acids Symp. Ser., 35, 125–126]. Phosphorothioate (PS) analogs of MBOs destabilize the duplex with the DNA target strand more than the duplex with the RNA target strand. Circular dichroism studies indicate that the duplexes of MBOs with the DNA and RNA target strands have spectral characteristics of both A- and B-type conformations. Compared with the control oligonucleotide, MBOs exhibit moderately higher stability against snake venom phosphodiesterase, S1 nuclease and in fetal calf serum. Although 2′–5′ modification does not evoke RNase H activity, this modification does not effect the RNase H activation property of the 3′–5′-deoxyribonucleotide segment adjacent to the modification. In vitro studies with MBOs suggest that they have lesser effects on cell proliferation, clotting prolongation and hemolytic complement lysis than do control PS oligodeoxyribonucleotides. PS analogs of MBOs show HIV-1 inhibition comparable with that of a control PS oligodeoxyribonucleotide with all 3′–5′ linkages. The current results suggest that a limited number of 2′–5′ linkages could be used in conjunction with PS oligonucleotides to further modulate the properties of antisense oligonucleotides as therapeutic agents." @default.
• W2098334967 created "2016-06-24" @default.
• W2098334967 creator A5002241220 @default.
• W2098334967 creator A5017047667 @default.
• W2098334967 creator A5019994958 @default.
• W2098334967 creator A5040780501 @default.
• W2098334967 creator A5069014764 @default.
• W2098334967 creator A5072695160 @default.
• W2098334967 creator A5088791437 @default.
• W2098334967 date "1997-01-15" @default.
• W2098334967 modified "2023-09-24" @default.
• W2098334967 title "Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'- 5'-deoxyribonucleotide segments" @default.
• W2098334967 cites W1027635430 @default.
• W2098334967 cites W1240040893 @default.
• W2098334967 cites W1447077155 @default.
• W2098334967 cites W1921475843 @default.
• W2098334967 cites W1949391242 @default.
• W2098334967 cites W1963871104 @default.
• W2098334967 cites W1973964951 @default.
• W2098334967 cites W2002763632 @default.
• W2098334967 cites W2009103135 @default.
• W2098334967 cites W2009366889 @default.
• W2098334967 cites W2009593695 @default.
• W2098334967 cites W2011684562 @default.
• W2098334967 cites W2022013776 @default.
• W2098334967 cites W2034908174 @default.
• W2098334967 cites W2039361749 @default.
• W2098334967 cites W2042017272 @default.
• W2098334967 cites W2047366876 @default.
• W2098334967 cites W2051581450 @default.
• W2098334967 cites W2054281456 @default.
• W2098334967 cites W2058950750 @default.
• W2098334967 cites W2060606238 @default.
• W2098334967 cites W2067171614 @default.
• W2098334967 cites W2069955207 @default.
• W2098334967 cites W2075935074 @default.
• W2098334967 cites W2079242913 @default.
• W2098334967 cites W2080160135 @default.
• W2098334967 cites W2088348110 @default.
• W2098334967 cites W2090819044 @default.
• W2098334967 cites W2091667528 @default.
• W2098334967 cites W2095602166 @default.
• W2098334967 cites W2161095956 @default.
• W2098334967 cites W2275740247 @default.
• W2098334967 cites W2406870179 @default.
• W2098334967 cites W4850913 @default.
• W2098334967 doi "https://doi.org/10.1093/nar/25.2.370" @default.
• W2098334967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/146429" @default.
• W2098334967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9016567" @default.
• W2098334967 hasPublicationYear "1997" @default.
• W2098334967 type Work @default.
• W2098334967 sameAs 2098334967 @default.
• W2098334967 citedByCount "56" @default.
• W2098334967 countsByYear W20983349672012 @default.
• W2098334967 countsByYear W20983349672015 @default.
• W2098334967 countsByYear W20983349672016 @default.
• W2098334967 countsByYear W20983349672018 @default.
• W2098334967 countsByYear W20983349672019 @default.
• W2098334967 countsByYear W20983349672020 @default.
• W2098334967 countsByYear W20983349672021 @default.
• W2098334967 crossrefType "journal-article" @default.
• W2098334967 hasAuthorship W2098334967A5002241220 @default.
• W2098334967 hasAuthorship W2098334967A5017047667 @default.
• W2098334967 hasAuthorship W2098334967A5019994958 @default.
• W2098334967 hasAuthorship W2098334967A5040780501 @default.
• W2098334967 hasAuthorship W2098334967A5069014764 @default.
• W2098334967 hasAuthorship W2098334967A5072695160 @default.
• W2098334967 hasAuthorship W2098334967A5088791437 @default.
• W2098334967 hasBestOaLocation W20983349671 @default.
• W2098334967 hasConcept C104317684 @default.
• W2098334967 hasConcept C10879258 @default.
• W2098334967 hasConcept C129312508 @default.
• W2098334967 hasConcept C153911025 @default.
• W2098334967 hasConcept C24107716 @default.
• W2098334967 hasConcept C2777271071 @default.
• W2098334967 hasConcept C552990157 @default.
• W2098334967 hasConcept C55493867 @default.
• W2098334967 hasConcept C67705224 @default.
• W2098334967 hasConcept C69766542 @default.
• W2098334967 hasConcept C86803240 @default.
• W2098334967 hasConceptScore W2098334967C104317684 @default.
• W2098334967 hasConceptScore W2098334967C10879258 @default.
• W2098334967 hasConceptScore W2098334967C129312508 @default.
• W2098334967 hasConceptScore W2098334967C153911025 @default.
• W2098334967 hasConceptScore W2098334967C24107716 @default.
• W2098334967 hasConceptScore W2098334967C2777271071 @default.
• W2098334967 hasConceptScore W2098334967C552990157 @default.
• W2098334967 hasConceptScore W2098334967C55493867 @default.
• W2098334967 hasConceptScore W2098334967C67705224 @default.
• W2098334967 hasConceptScore W2098334967C69766542 @default.
• W2098334967 hasConceptScore W2098334967C86803240 @default.
• W2098334967 hasIssue "2" @default.
• W2098334967 hasLocation W20983349671 @default.
• W2098334967 hasLocation W20983349672 @default.
• W2098334967 hasLocation W20983349673 @default.
• W2098334967 hasLocation W20983349674 @default.
• W2098334967 hasOpenAccess W2098334967 @default.
• W2098334967 hasPrimaryLocation W20983349671 @default.

• next